Upregulation of the PI3K/AKT and Nrf2 Pathways by the DPP-4 Inhibitor Sitagliptin Renders Neuroprotection in Chemically Induced Parkinson’s Disease Mouse Models
ACS Chemical Neuroscience · 2025
DOI: 10.1021/acschemneuro.5c00112 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Chemical Neuroscience, 2025. Verfasst von Ritu Soni und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Institute of Pharmacy, Nirma University, Ahmedabad, Gujarat 382481, India. Hauptthemen laut MEDLINE: Sitagliptin Phosphate, NF-E2-Related Factor 2, Proto-Oncogene Proteins c-akt, Neuroprotective Agents. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: NextGenerationEU, Gujarat State Biotechnology Mission, Government of Gujarat, India.
Abstract (Originalsprache)
Parkinson's disease (PD) is one of the most common progressive neurodegenerative pathologies that leads to dopaminergic deficiency and motor manifestations. Alpha-synuclein aggregation is a characteristic hallmark of PD pathogenesis. These aggregates facilitate the formation of Lewy bodies and degeneration. The epidemiological evidence demonstrates a definitive association of diabetes with PD risk. Considering this, many antidiabetic agents such as GLP-1 agonists and DPP-4 inhibitors are being explored as alternative PD therapeutics. This study evaluated the neuroprotective effect of the DPP-4 inhibitor sitagliptin mediated by the PI3K/AKT and Nrf2 pathways in PD models. In silico studies were conducted to determine the binding affinity, stability, and ADMET properties of DPP-4 inhibitors with target proteins. Sitagliptin (15 mg/kg p.o.) was administered in rotenone (30 mg/kg p.o. for 28 days)-induced and MPTP/P (25 mg/kg i.p. MPTP and 100 mg/kg probenecid i.p. twice a week for 5 weeks)-induced PD mouse (C57/BL6) models. Neurobehavioral assessments were carried out throughout the study. Biochemical (GSH, MDA), molecular estimations (AKT, Nrf2, PI3K, GSK-3β, GLP1, CREB, BDNF, NF-κB, alpha-synuclein), histopathological studies, and immunohistochemistry were carried out at the end of the study. The in silico studies demonstrate better binding, stability, and ADMET profile of sitagliptin with both target proteins. Sitagliptin restored cognitive and motor deficits in both rotenone- and MPTP/P-induced mouse models. There was upregulation of PI3K, AKT, Nrf2, CREB, and BDNF levels and downregulation of GSK-3β, NF-κB, and alpha-synuclein levels in both models after treatment with sitagliptin. However, GLP1 levels were not significantly restored, indicating a GLP1-independent mechanism. It also restored histopathological alterations and TH+ neuronal loss induced by rotenone and MPTP/P. These findings demonstrate that sitagliptin exhibits neuroprotective action mediated by upregulation of the PI3K/AKT and Nrf2 pathways in rotenone and MPTP/P mouse models of PD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, Institute of Pharmacy, Nirma University, Ahmedabad, Gujarat 382481, India.
- Department of Biomedical Engineering, Faculty of Electrical Engineering and Communication, Brno University of Technology, Brno 61600, Czechia.
- International Clinical Research Centre, St. Anne's University Hospital Brno (FNUSA-ICRC), Brno 60200, Czech Republic.
- Department of Physiology, Faculty of Medicine, Masaryk University, Kamenice 753/5, Brno 62500, Czechia.
- International Clinical Research Centre, Faculty of Medicine, Masaryk University, Kamenice 753/5, Brno 62500, Czechia.
ORCID-Profile: Ritu Soni, Amit Khairnar, Jigna Shah
Förderung
- NextGenerationEU
- Gujarat State Biotechnology Mission, Government of Gujarat, India
Zitieren
APA
Soni, R., Pankaj, V., Roy, S., Khairnar, A., & Shah, J. (2025). Upregulation of the PI3K/AKT and Nrf2 Pathways by the DPP-4 Inhibitor Sitagliptin Renders Neuroprotection in Chemically Induced Parkinson’s Disease Mouse Models. ACS Chemical Neuroscience. https://doi.org/10.1021/acschemneuro.5c00112
Vancouver
Soni R, Pankaj V, Roy S, Khairnar A, Shah J. Upregulation of the PI3K/AKT and Nrf2 Pathways by the DPP-4 Inhibitor Sitagliptin Renders Neuroprotection in Chemically Induced Parkinson’s Disease Mouse Models. ACS Chemical Neuroscience. 2025. doi:10.1021/acschemneuro.5c00112
BibTeX
@article{Soni2025,
author = {Soni, Ritu and Pankaj, Vaishali and Roy, Sudeep and Khairnar, Amit and Shah, Jigna},
title = {Upregulation of the PI3K/AKT and Nrf2 Pathways by the DPP-4 Inhibitor Sitagliptin Renders Neuroprotection in Chemically Induced Parkinson’s Disease Mouse Models},
journal = {ACS Chemical Neuroscience},
year = {2025},
doi = {10.1021/acschemneuro.5c00112}
}
EUVIMED